This investigational compound is engineered to concurrently engage three distinct pathways that regulate appetite, energy expenditure, and glucose homeostasis, a strategy that differentiates it from previous therapeutic classes
Figure 2: Higher insulin levels increase transmethylation, raising homocysteine (Hcy) levels and reducing cysteine
MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) and is associated with chronic inflammation that causes progressive fibrosis, which may lead to cirrhosis and/or hepatocellular carcinoma (HCC) 3,4
It develops over time due to a combination of risk factors, including: Excess body weight High blood pressure Elevated cholesterol Blood sugar instability Chronic inflammation The encouraging news
Doses are adjusted based on response, and safety checks cover potential side effects or lab abnormalities
Cost is the practical advantagecompounded therapy at $149/month avoids insurance denials and retail markups
